论文部分内容阅读
目的观察及评价胸腺肽α1(Tα1)对恶性肿瘤患者的辅助治疗作用。方法将56例恶性肿瘤患者随机分为观察组和对照组,每组28例。两组均给予2个周期的化疗,观察组从化疗当天开始联合应用Tα11.6mg,肌内注射,3次/周。结果胸腺肽组胃肠道反应发生率明显低于对照组(p<0.01),观察组化疗后CD4、CD4/CD8、NK细胞活性高于化疗前和对照组化疗后水平(p<0.01)。对照组NK细胞活性低于化疗前水平(p<0.01)。结论 Tα1对恶性肿瘤具有辅助治疗作用,配合化疗能提高恶性肿瘤患者的免疫功能,改善生活质量。
Objective To observe and evaluate the adjuvant therapeutic effect of thymosin α1 (Tα1) on patients with malignant tumors. Methods 56 patients with malignant tumor were randomly divided into observation group and control group, 28 cases in each group. Both groups were given 2 cycles of chemotherapy, and the observation group began to use Tα 11.6 mg combined with intramuscular injection 3 times/week from the day of chemotherapy. Results The incidence of gastrointestinal reactions in the thymosin group was significantly lower than that in the control group (p<0.01). The activity of CD4, CD4/CD8 and NK cells in the observation group after chemotherapy was higher than that before chemotherapy and in the control group after chemotherapy (p<0.01). The activity of NK cells in the control group was lower than that before chemotherapy (p<0.01). Conclusion Tα1 has an adjuvant therapeutic effect on malignant tumors. Combined with chemotherapy, it can improve the immune function of patients with malignant tumors and improve the quality of life.